## Bereskin & Parr



Barristers and Solicitors/Patent and Trade Mark Agents Practice Restricted to Intellectual Property Law

April 9, 2001

Anita Nador B.A. (Molec. Biophys./Biochem), LL.B. 416 957 1684 anador@bereskinparr.com

Our Reference:

11014-24

The Commissioner of Patents and Trademarks Washington, D.C. U.S.A. 20231

Dear Sir:

Re:

**U.S. Regular Patent Application** 

Claiming Priority from U.S. Provisional Patent Application No. 60/195,456

Entitled:

Immunogenic Peptides Derived From Prostate-

Specific Antigen (PSA) and Uses Thereof

Inventors: Artur Pedyczak, Pele Chong, Charles D.Y. Sia

Applicants are submitting the above-identified patent application for filing at the United States Patent and Trademark Office.

Applicants are submitting herewith (1) a Sequence Listing in paper form; (2) a Sequence Listing in computer readable form (a 3.5" floppy diskette) in the ASCII format and (3) a statement (set forth below) that the paper form and the computer readable form of the Sequence Listing are the same.

In accordance with the requirements of 37 C.F.R. 1.821-1.825 the undersigned verifies that the paper form of the Sequence Listing and the computer readable form of the Sequence Listing are the same.

Respectfully submitted

ARTHUR PEDYCZAK, PELE CHONG CHARLES D.Y. SIA

Anita Nador

Registration No. 47,366

**BERESKIN & PARR** 

(Agents for the Applicants)

Enclosure

<210> 3

## SEQUENCE LISTING

```
<110> Chong, Pele
     Pedyczak, Artur
     Sia, Charles Dwo Yuan
<\!120\!> Immunogenic Peptides Derived from Prostate-Specific Antigen (PSA) and Uses Thereof
<130> 11014-24
<150> US 60/195,456
<151> 2000-04-10
<160> 12
<170> PatentIn version 3.0
<210> 1
<211> 8
<212> PRT
<213> Artificial
<220>
<223> CLP313
<400> 1
Met Trp Val Pro Val Val Phe Leu 5
<210> 2
<211> 9
<212> PRT
<213> Artificial
<220>
<223> CLP314
<400> 2
```

```
<211> 9
 <212> PRT
 <213> Artificial
 <220>
 <223> CLP316
 <400> 3
 Lys Leu Gln Cys Val Asp Leu His Val 1
 <210> 4
 <211> 9
 <212> PRT
<213> Artificial
<220>
<223> CLP315
<400> 4
<210> 5
<211> 9
<212> PRT
<213> Artificial
<220>
<223> CLP317
<400> 5
Asp Leu His Val Ile Ser Asn Asp Val 1
<210> 6
<211> 9
<212> PRT
<213> Artificial
<220>
<223> CLP320
<400> 6
Pro Leu Tyr Asp Met Ser Leu Leu Lys 1
```

<210>	7	
<211>	24	
<212>	DNA	
<213>	Artificial	
<220>		
<223>	CLP313	
<400> atgtgg	7 gtcc cggttgtctt cctc	24
<210>	8	
<211>	27	
<212>	DNA	
<213>	Artificial	
<220>		
<223>	CLP314	
<400> gttctg	8 gtgc accccagtg ggtcctc	27
.04.0		
<210>		
<211>		
<212>		
\213>	Artificial	
<220>		
<223>	CLP316	
<400> aaactt	9 cagt gtgtggacct ccatgtt	27
<210>	10	
<211>	27	
<212>	DNA	
<213>	Artificial	
<220>		
<223>	CLP315	
<400> gacctgd	10 ccca cccaggagcc agcactg	27
<210>	11	

, . . .

```
<211> 27
<212> DNA
<213> Artificial
<220>
<223> CLP317
<400> 11
gacctccatg ttatttccaa tgacgtg
                                                                   27
<210> 12
<211> 27
<212> DNA
<213> Artificial
<220>
<223> CLP320
<400> 12
ccgctctacg atatgagcct cctgaag
                                                                   27
```